A clue hidden in a simple experiment
Here is one of endocrinology's most elegant findings. Give a person glucose to drink, and their beta cells release a large surge of insulin. Now give the *same amount* of glucose directly into a vein, raising blood sugar to the same level — and the insulin response is noticeably smaller. The mouth and the vein deliver identical glucose, yet the pancreas reacts more strongly to the meal. Something from the gut is amplifying the response. That something is the family of incretins.
The two main incretins are glucagon-like peptide-1 (GLP-1), from L cells in the lower small intestine, and GIP, from K cells higher up. Both are enteroendocrine products released as nutrients are absorbed. They reach the pancreas and tell the beta cells, in effect, “food is genuinely on the way — get ready to handle it.” This is feedforward anticipation: the pancreas is warned before blood glucose has even peaked.
GLP-1 does more than nudge insulin
GLP-1 turned out to be a many-handed messenger. Beyond amplifying insulin, it suppresses glucagon (the hormone that raises blood sugar), slows gastric emptying so glucose enters the blood more gently, and acts on the brain to increase satiety. Each of these pushes blood glucose in the same helpful direction and, by curbing appetite, can reduce how much a person eats.
This breadth is exactly why GLP-1 became a drug target. Native GLP-1 is destroyed within minutes by an enzyme, so the molecule itself is useless as a once-a-day medicine. Engineered, longer-lasting versions (GLP-1 receptor agonists) keep the signal switched on, lowering blood sugar in type 2 diabetes and producing substantial weight loss. The whole class is a vivid demonstration that a humble gut hormone can reshape a major field of medicine.